SHCSotera Health Company
Is the price fair?
The yardsticks disagree: cheap against its own 5-year P/E range (13th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.
Priced for ~17% a year FCF growth. The price demands more than its three-year revenue growth of 8% a year, priced for acceleration.
Cheap vs its own history: P/E 31.8 vs a 66.1 median over 16 quarters (−52% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SHC's price assumes
Sotera Health Company trades at 31.8× earnings against 36.7× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 36.7 · cheaper than the typical name in its group
- Price / sales
- 4.25
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 2.2%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; revenue has grown 7.6% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 7.76
- EV / salestoday's price, trailing year to Jun 30, 2026
- 5.71
- Healthcare median P/E503 names
- 27.9
- Diagnostics & Research median P/E33 names
- 36.7
- Free cash flow, trailing twelve months
- $113M
- Market capitalisation285.4 million shares, counted Jul 30, 2026
- $5.17B
- 3-year revenue growth
- +7.6%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 31.8× today against a 66.1× median |
| 52-week range | $13.13 – $19.58 |
| Today | $18.10 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
Ranks #3 of 21 by RyuScore